Aller au contenu principal
Aller au contenu principal

Andréanne Gagné

Médecin clinicienne enseignante sous octroi adjointe
Faculté de médecine
Dép. biologie moléculaire, biochimie médicale et pathologie

andreanne.gagne.4@ulaval.ca

Consulter l'ORCID de Andréanne Gagné

Disponible pour l'encadrement

Domaines de recherche

  • Pathologie (sauf la pathologie buccale)
  • Cibles moléculaires du cancer
  • Génétique du cancer
  • Métastases et progression du cancer
  • Diagnostic du cancer
  • Médecine cardiorespiratoire et hématologie, n.c.a.

  • Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec (Affilié à l’Université Laval)
  • Centre de recherche sur le cancer
  • Groupe de recherche en santé respiratoire

Caractérisation spatiale et moléculaire du microenvironnement tumoral dans les carcinomes pulmonaires : développement de nouveaux biomarqueurs pour optimiser la stratification des patients

Programme: Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors

Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé

Type de financement: Subvention

Établissement tête: Université Laval

Du 1 juillet 2026 au 30 juin 2030

Caractérisation spatiale et moléculaire du microenvironnement tumoral dans les carcinomes pulmonaires : développement de nouveaux biomarqueurs pour optimiser la stratification des patients

Programme: Établissement de jeunes chercheurs cliniciens et jeunes chercheuses cliniciennes - Junior 1

Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Santé

Type de financement: Subvention

Établissement tête: Université Laval

Du 1 juillet 2026 au 30 juin 2030

Determinants of durable immunotherapy response in non-small cell lung cancer

Programme: Subvention de fonctionnement

Organisme(s) subventionnaire(s): Société de recherche sur le cancer

Type de financement: Subvention

Établissement tête: Université Laval

Du 1 septembre 2025 au 31 août 2027

Caractérisation des altérations de SMARCA4 et de SMARCA2 dans les adénocarcinomes pulmonaires de stade précoce

Organisme(s) subventionnaire(s): Fondation de l'Université Laval

Type de financement: Subvention

Établissement tête: Université Laval

Du 2 décembre 2024 au 1 décembre 2026

  • Camryn Bass, Maîtrise en médecine moléculaire - avec mémoire
  • Kelly-Ann Pellerin, Maîtrise en sciences cliniques et biomédicales - avec mémoire

Travaux de recherche des 5 dernières années

Moving Beyond Morphology to Multiplexed Molecular Imaging as the Next Frontier in Diagnostic Pathology The American Journal of Pathology, 2026. Andréanne Gagné, Jia-Ren Lin. DOI 10.1016/j.ajpath.2026.03.015

Modeling development of tertiary lymphoid structures in pulmonary tuberculosis by 3D profiling and trajectory analysis 2026. Emmanuel C. Ogbonna, Soheil R. Talemi, Zoltan Maliga, Ziyuan Zhao, Clarence Yapp, Shishir M. Pant, Yi Daniel Lu, Jeremy Muhlich, Andréanne Gagné, Amanda J. Martinot, Shannon Coy, Sandro Santagata, Angela R. Shih, Isaac H. Solomon, Threnesan Naidoo, Bree B. Aldridge, Adrie J.C. Steyn, Peter K. Sorger. DOI 10.64898/2026.06.02.725201

Compositional and interpretable representation of histology using AI foundation models and sparse autoencoders 2026. Ziyuan Zhao, Zoltan Maliga, Emmanuel C. Ogbonna, Soheil R. Talemi, Shannon Coy, Andréanne Gagné, Kapongo Lumamba, Isaac H. Solomon, Sandro Santagata, Adrie J.C. Steyn, Threnesan Naidoo, Peter K. Sorger. DOI 10.64898/2026.06.03.725182

Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas Lung Cancer, 2025. Andréanne Gagné, Joao Victor M. Alessi, Biagio Ricciuti, Giuseppe Lamberti, Mark M. Awad, Lynette M. Sholl. DOI 10.1016/j.lungcan.2025.108644

Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project Lung Cancer, 2025. Yohan Bossé, Dominique K. Boudreau, Victoria Saavedra Armero, Zhonglin Li, Élody Tremblay, Nathalie Gaudreault, Andréanne Gagné, Patrice Desmeules, Philippe Joubert. DOI 10.1016/j.lungcan.2025.108530

Impact of Implementing a Grossing Tumor-margin Distance Threshold for Frozen Section in Oncologic Lung Surgery AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2025. DOI 10.1097/PAS.0000000000002337

Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes LUNG CANCER, 2025. DOI 10.1016/J.LUNGCAN.2025.108596

Clinicopathological Predictors of the Presence of Blood Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancers MODERN PATHOLOGY, 2025. DOI 10.1016/J.MODPAT.2025.100744

A Comprehensive Evaluation of Clinicopathologic Characteristics, Molecular Features and Prognosis in Lung Adenocarcinoma with an Acinar Component CANCERS, 2025. DOI 10.3390/CANCERS17111825

Whole-slide multiplexed tissue imaging of prostate adenocarcinoma to investigate immune niches in high- versus low-grade tumors. JOURNAL OF CLINICAL ONCOLOGY, 2025. DOI 10.1200/JCO.2025.43.5_SUPPL.224

Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma CELL REPORTS MEDICINE, 2025. DOI 10.1016/J.XCRM.2025.102188

Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patients JOURNAL OF TRANSLATIONAL MEDICINE, 2025. DOI 10.1186/S12967-025-06487-2

Multiomic analysis identifies suppressive myeloid cell populations in human TB granulomas. bioRxiv, 2025. DOI 10.1101/2025.03.10.642376

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors JTO CLINICAL AND RESEARCH REPORTS, 2025. DOI 10.1016/J.JTOCRR.2024.100759

Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers 2024. Jeremiah Wala, Ino de Bruijn, Shannon Coy, Andréanne Gagné, Sabrina Chan, Yu-An Chen, John Hoffer, Jeremy Muhlich, Nikolaus Schultz, Sandro Santagata, Peter K Sorger. DOI 10.1101/2024.09.24.614701

Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma 2024. Josephine Yates, Camille Mathey-Andrews, Jihye Park, Amanda Garza, Andréanne Gagné, Samantha Hoffman, Kevin Bi, Breanna Titchen, Connor Hennessey, Joshua Remland, Erin Shannon, Sabrina Camp, Siddhi Balamurali, Shweta Kiran Cavale, Zhixin Li, Akhouri Kishore Raghawan, Agnieszka Kraft, Genevieve Boland, Andrew J. Aguirre, Nilay S. Sethi, Valentina Boeva, Eliezer Van Allen. DOI 10.1101/2024.08.17.608386

Implementing a Grossing Tumor Margin Distance Threshold of 2.0 cm for Frozen Section in Oncologic Lung Surgery: A Validation Study LABORATORY INVESTIGATION, 2024.

Spatial Profiling of the Tumor Microenvironment of SMARCA4-Mutant NSCLCs Using Whole-Slide Multiplex Fluorescence Imaging JOURNAL OF THORACIC ONCOLOGY, 2024.

Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less <i>KRAS</i> and More <i>EGFR</i> Mutations Compared to Advanced Adenocarcinomas INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024. DOI 10.3390/IJMS25052959

Whole-slide multiplexed tissue imaging of prostate adenocarcinoma reveals distinct immune niches in high- versus low-grade tumors CANCER RESEARCH, 2024. DOI 10.1158/1538-7445.AM2024-5558

Comparative Assessment of Multiple PD-L1 Antibodies on the Same Slide Using Multiplex Tissue-Based Cyclic Immunofluorescence LABORATORY INVESTIGATION, 2024.

Reporting of Incidental Thrombotic Arteriopathy in Lung Resection Specimens AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2024. DOI 10.1097/PAS.0000000000002292

Characteristics and Outcomes of Patients with SMARCA4-Deficient Undifferentiated Thoracic Tumors JOURNAL OF THORACIC ONCOLOGY, 2024.

Clinical Outcomes of Resected Pure Ground-Glass, Heterogeneous Ground-Glass, and Part-Solid Pulmonary Nodules AMERICAN JOURNAL OF ROENTGENOLOGY, 2024. DOI 10.2214/AJR.23.30504

Association of Clinicopathological and Molecular Features with the Prognosis of KRAS Mutation Subtypes in Lung Adenocarcinoma LABORATORY INVESTIGATION, 2024.

CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma CANCERS, 2024. DOI 10.3390/CANCERS16040708

A Simplified Version of the IASLC Grading System for Invasive Pulmonary Adenocarcinomas With Improved Prognosis Discrimination AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2023. DOI 10.1097/PAS.0000000000002040

Single-cell spatial landscapes of the lung tumour immune microenvironment NATURE, 2023. DOI 10.1038/S41586-022-05672-3

Tertiary Lymphoid Aggregates as a Predictive Biomarker of Immunotherapy Treatment Response in Patients with NSCLC LABORATORY INVESTIGATION, 2023.

CXCL13 Positive Cells Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non Small Cell Carcinoma LABORATORY INVESTIGATION, 2023.

Amplification of wild-type <i>RET</i> and clinical response to selpercatinib for non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 2023. DOI 10.1200/JCO.2023.41.16_SUPPL.9123

Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023. DOI 10.1136/JITC-2022-005545

Amplification of wild-type RET and clinical response to selpercatinib for non-small-cell lung cancer (NSCLC) JOURNAL OF CLINICAL ONCOLOGY, 2023.

Amplification of Wild-Type <i>RET</i> Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib JCO PRECISION ONCOLOGY, 2023. DOI 10.1200/PO.23.00295

Comparison of Tumor Immune Microenvironment Using Imaging Mass Cytometry in Patients with Synchronous Lung Adenocarcinomas LABORATORY INVESTIGATION, 2023.

Generalization optimizing machine learning to improve CT scan radiomics and assess immune checkpoint inhibitors' response in non-small cell lung cancer: a multicenter cohort study FRONTIERS IN ONCOLOGY, 2023. DOI 10.3389/FONC.2023.1196414

Clinical Impact of Reporting Incidental Thrombotic Arteriopathy in Lung Resection Specimens LABORATORY INVESTIGATION, 2023.

Prognostic value of complex glandular patterns in invasive pulmonary adenocarcinomas HUMAN PATHOLOGY, 2022. DOI 10.1016/J.HUMPATH.2022.07.007

Original Contribution Prognostic Value of Complex Glandular Patterns in Invasive Pulmonary Adenocarcinomas 2022. Yohan Bossé, Andréanne Gagné, Wajd Ahmed Althakfi, Michèle Orain, Pierre Olivier Fiset, Patrice Desmeules, Philippe Joubert. DOI 10.2139/ssrn.4112045

Wait Times and Survival in Lung Cancer Patients across the Province of Quebec, Canada CURRENT ONCOLOGY, 2022. DOI 10.3390/CURRONCOL29050259

Gut microbiota and fermentation-derived branched chain hydroxy acids mediate health benefits of yogurt consumption in obese mice NATURE COMMUNICATIONS, 2022. DOI 10.1038/S41467-022-29005-0

ZNF768 Expression Associates with High Proliferative Clinicopathological Features in Lung Adenocarcinoma CANCERS, 2021. DOI 10.3390/CANCERS13164136

Heterogeneity of Immune Biomarkers in Patients with Synchronous Lung Adenocarcinomas MODERN PATHOLOGY, 2021.

Thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. JOURNAL OF CLINICAL ONCOLOGY, 2021. DOI 10.1200/JCO.2021.39.15_SUPPL.E21198

Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study THROMBOSIS RESEARCH, 2021. DOI 10.1016/J.THROMRES.2021.06.018

ZNF768 links oncogenic RAS to cellular senescence NATURE COMMUNICATIONS, 2021. DOI 10.1038/S41467-021-24932-W

Les informations contenues dans cette page sont extraites de différents systèmes experts de l’Université Laval. Si vous constatez une erreur ou avez des questions quant aux données affichées, communiquez avec nous en écrivant à l’adresse repertoire-corps-professoral@ulaval.ca. Nous nous assurerons de rediriger votre demande à la bonne personne.